Clinical Trial Update: Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

View source ↗

Summary

A completed clinical trial evaluating high-dose chemotherapy combined with adoptive dendritic cell-CIK cell therapy in patients with triple-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• DC-CIK cells (dendritic cell-cytokine-induced killer cells)
• High-dose chemotherapy (high-dose chemotherapy)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Breast Neoplasms, Neoplasm Metastasis | Status: COMPLETED